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  46 
ABSTRACT 47 
 48 
The effect of the PPh3 group in the antitumor activity of some new organometallic ruthenium(II) 49 
complexes has been investigated. Several complexes of the type [Ru(II)(Cl)(PPh3)(Lig-N)], 50 
[Ru(II)(Cl)2(Lig-N)] (where Lig-N= pyridine derivate) and [Ru(II)(Cl)(PPh3)2], have been synthesized 51 
and characterized. A noticeable increment of the antitumor activity and cytotoxicity of the complexes 52 
due to the presence of PPh3 moiety has also been demonstrated, affording IC50 values of 5.2 μM in HL-53 
60 tumor cell lines. Atomic force microscopy, circular dichroism and electrophoresis experiments have 54 
proved that these complexes can bind DNA resulting in a distortion of both secondary and tertiary 55 
structures. Ethidium bromide displacement fluorescence spectroscopy studies and viscosity 56 
measurements support that the presence of PPh3 group induces intercalation interactions with DNA. 57 
Indeed, crystallographic analysis, suggest that intra-molecular π–π interactions could be involved in the 58 
intercalation within DNA base pairs. Furthermore, high performance liquid chromatography mass 59 
spectrometry (HPLC–MS) studies have confirmed a strong interaction between ruthenium complexes 60 
and proteins (ubiquitin and potato carboxypeptidase inhibitor — PCI) including slower kinetics due to 61 
the presence of PPh3 moiety,which could have an important role in detoxification mechanismand others. 62 
Finally, ion mobility mass spectrometry (IMMS) experiments have proved that there is no significant 63 





  69 
1. INTRODUCTION 70 
 71 
In the last few years, ruthenium complexes have attracted much attention as building blocks for new 72 
transition-metal-based antitumor agents, since they present some advantages over platinum complexes 73 
currently used in cancer chemotherapy [1,2]. Ruthenium compounds show less toxicity, a novel 74 
mechanism of action, the prospect of noncross-resistance [3,4] and a different spectrum of activity [5,6]. 75 
More concretely, organometallic ruthenium(II) complexeswith arene ligands represent an important 76 
group of rutheniumcompoundswith anticancer activity that is being intensively studied in the last 77 
decades [7]. The typical structure of organometallic ruthenium complexes bearing η6- arene ligands is 78 
shown in Fig. 1, which consist in a half-sandwich “piano-stool” [(η6-arene)Ru(X)(Y)(Z)] complex, 79 
where X is usually a monodentate leaving group and Y, Z can be monodentate or chelating ligands, 80 
depending on the porpoise of the design [8,9]. 81 
These half sandwich “piano-stool” type constructs offermuch scope for design, with the potential for 82 
modifications to the arene and its substituents (R), the monodentate leaving group (X), the ligands Y and 83 
Z, and overall charge of the complex (n+). These features provide handles for the control of both the 84 
thermodynamics and kinetics of these systems as well as their overall structural architecture, allowing a 85 
more rational drug design approach compared to platinum-based drugs [10]. They also provide an ability 86 
to fine-tune the chemical reactivity of the complexes, potentially allowing the control of 87 
pharmacological properties including cell uptake, distribution, and interactionswith biomolecules, toxic 88 
side effects, and detoxification mechanisms [11]. 89 
With regard to their mechanism of action, the role of the arene moiety, as well as the influence of the 90 
other ligands on the aqueous chemistry of several complexes have been widely investigated [12–18], 91 
resulting in a complex structure–activity relationship [7]. As observed for other ruthenium complexes, 92 
their cytotoxicity is usually correlated with DNA binding [19–21], although recent works point to other 93 
biomolecules as possible biological targets. As an example, RAPTA complexes do not show selective 94 
binding to DNA in vitro, and proteins and RNA appear to be the main intracellular targets [22]. In the 95 
same way, in the case of the NAMI-A antimetastatic agent, it is apparent that DNA is not the target, and 96 
more likely, activity is a consequence of drug–protein interaction. This is especially interesting since the 97 
antimetastatic behavior is not unique to NAMI-A, but applicable to other classes of ruthenium 98 
complexes [23,24]. Related to these results, here we explore the interaction of η6-arene ruthenium(II) 99 
complexes with some specific proteins. 100 
Lastly, previousworks suggests that the addition of the hydrophobic PPh3 ligand in RAPTA complexes 101 
results in more cytotoxic and less selective drugs, presumably because of increased drug uptake [22]. 102 
With the aim of developing more potent anticancer drugs, we have synthesized and characterized six 103 
new organometallic arene–ruthenium(II) complexes, some of them including PPh3 group in its structure. 104 
In this work we study the influence of tri-phenyl-phosphine moiety in the antitumor activity of several 105 
η6-arene ruthenium(II) complexes, and try to elucidate the possible reason behind this phenomenon. 106 
  107 
2. EXPERIMENTAL 108 
 109 
2.1. Materials 110 
 111 
2.1.1. Reactives 112 
RuCl3, pyridine derivated ligands and methyl-benzylamines, were purchased from Fluka. KPF6, 113 
NH4PF6, salts used for buffer preparation, mobile phases and ubiquitin were commercial products from 114 
Sigma-Aldrich. Solvents were purchased from Sigma-Aldrich and Panreac. Ligand dppz was 115 
synthesized fromSigma-Aldrich commercial products. PCI was extracted directly from potato. 116 
 117 
2.1.2. Solutions and buffers 118 
TE: 10 nM tris-HCl (tris-[hydroxymethyl]aminomethane hydrochloride), 119 
0,1 mM EDTA (ethylenediaminetetraacetic acid), 50 mM NaCl; pH was adjusted to 7.4 with NaOH. 120 
TBE: 45 mM tris-base (tris-[hydroxymethyl]aminomethane), 45 mM boric acid, 1 mM EDTA 121 
(ethylenediaminetetraacetic acid); pH was adjusted to 8 with NaOH. HEPES: 40 mM de HEPES (4-(2-122 
hydroxyethyl)-1-piperazineethane sulfonic acid), 10 mM MgCl2; pH was adjusted to 7.4 with NaOH 123 
 Color marker: bromophenol blue (0.25%), xilencianol FF (0.25%),  glycerol 25%. 124 
PBS: 150mMNaCl, 3mMKCl, 9mMNa2PO4, 1.3mMK2PO4; pHwas adjusted to 7.2 with NaOH. 125 
 126 
2.1.3. DNA and general materials for DNA experiments 127 
DNA calf thymus highly polymerized sodium salt (SIGMA); Plasmid pBR322 0.25 μg/μl (Boehringer 128 
Mannheim GmbH); Agarose AG-200 molecular biology grade (ECOGEN); ethidium bromide 129 
(MERCK). 130 
 131 
2.1.4. Protein solutions preparation. Proteins: Ubiquitin and potato carboxypeptidase inhibitor (PCI) 132 
Ubiquitin 3 mM solution was prepared dissolving commercial lyophilized ubiquitin in mQ water. PCI 133 
solution 1.86 mM was prepared dissolving the protein directly extracted from potato, in mQ water. 134 
Protein concentration was determined in both cases through absorbance measurements with UV–visible 135 
(UV–Vis) spectrophotometer CARY 100 SCAN (Varian) as predicted by Lambert–Beer theory. Molar 136 
absorptivity coefficient estimation was made with the method proposed by Grimsley et al. [25]. 137 
 138 
2.2. Devices and methods 139 
 140 
2.2.1. X-ray diffraction analysis 141 
Crystal structures were registered with an ENRAF-NONIUS CAD4. Software for structure refining was 142 
SHELXS97 and SHELXL97. Crystals were obtained through diethyl ether slowdiffusion in saturated 143 
dichloromethane solutions of the compounds. 144 
2.2.2. Elemental analysis 145 
Elemental analysis of (C, H, N, S)was carried outwith a CARLO ERBA EA1108. 146 
 147 
2.2.3. Infrared spectroscopy 148 
IR spectra between 4000 and 600 cm−1 were registered with a spectrophotometer NICOLET 5700 FT-149 
IR, in solid phase in KBr matrix. 150 
 151 
2.2.4. NMR spectroscopy 152 
1H, 31P{1H} and 19F{1H} NMR were registered in a 300 MHz VARIAN UNITY. Samples were 153 
dissolved in CDCl3.  154 
 155 
2.2.5. Atomic force microscopy (AFM) 156 
Atomic force microscopy images were obtained in TMAFM mode with a NANOSCOPE III 157 
MULTIMODE AFM from Digital Instruments Inc. 158 
Sample preparation: DNA was treated for 15 min at room temperature to obtain a homogeneous 159 
topoisomer distribution. Stock solution 1 mg/ml was prepared in a maximum rate DMSO:HEPES 6:4, 160 
for non water soluble complexes. It was then diluted 1:1000 in HEPES until a final volume of 2000 μl, 161 
and therefore filtered through FP030/3 0.2 nm pore filters (Schleicher & Schuell GmbH). Each sample 162 
consists of 1 μl of pBR-322 plasmid DNA (0.25 μg/μl), 2 μl of drug filtered solution and then carried to 163 
a final volume of 50 μl with HEPES. Samples were incubated during 5 and 24 h at 37 °C. 2 μl of each 164 
sample are adsorbed over a mica disk (Ashville-Schoonmaker Mica Co., Newport News), washed with 165 
mQ water and dried under argon or nitrogen. 166 
 167 
2.2.6. Circular dichroism 168 
Circular dichroism spectra were registered with a spectropolarimeter JASCO 810, equipped with a 169 
450WXenon arc lamp. 170 
Sample preparation: 1 mg/ml stock solutions of each compound were prepared immediately before using 171 
in a DMSO:TE sterilized mixture (2% DMSO maximum). 20 μg/ml calf thymus DNA solution was 172 
prepared in TE and stored at 4 °C. DNA quantization was verified by UV–Vis spectroscopy, checking 173 
absorbance at 260 nm in a split double beam SHIMADZU UV-2101-PC spectrophotometer. 174 
CompoundDNA adduct formation was carried out by addition of solution stock aliquots of each 175 
compound to a fixed volume of DNA solution. Amount of drug added in each case is expressed as ri 176 
(theoretical molar ratio compound–nucleotide) and is calculated as can be seen in the additional 177 
information.  178 
 179 
𝑟 =  
    
    
ri ¼ 180 
 181 
m  mass of compound used to prepare stock solution (μg) 182 
Mnucl  average molecular mass by nucleotide (g/mol) 183 
Am  number of metallic atoms in compound 184 
C  DNA solution concentration (μg/ml) 185 
Mr  molecular mass of each compound (g/mol) 186 
V  sample final volume (ml) 187 
 188 
All experiments were carried out for molar ratios of 0.1, 0.3 and 0.5, which means that in each case there 189 
are 1, 3 and 5 molecules of compound respectively versus each ten pairs of DNA nitrogen bases. 190 
Through this formula the μg of compound (or μl of stock solution) that must be added to DNA solution 191 
in each case can be calculated. The sample holder had 5 l/min nitrogen flowpurge. 1 cm path length 192 
quartz cells were used formeasurements. Each sample was registered twice in a wavelength interval of 193 
220 and 330 nm, rate of 50 nm/min. 194 
 195 
2.2.7. Agarose gel electrophoresis 196 
Electrophoresis experiments were carried out in an ECOGEN horizontal tank connected to a 197 
PHARMACIA GPS 200/400 variable tension source. Gel images were recorded with a thermal system 198 
FUJIFILM FTI-500. 199 
Sample preparation: stock solution preparation for each compound was the sameto the one described for 200 
circular dichroism. Buffer solution was TE (2% DMSO maximum). Sample final volume was 20 μl:2.8 201 
μl of DNA pBR322 solution 0.25 μg/μl, the volume of stock solution necessary to obtain the 202 
desiredmolar ratio (ri= 0.5), and filling until 20 μlwithTE buffer solution. In this way, the final 203 
concentration of DNA plasmid was 35 μg/ml so each sample contained 0.7 μg of DNA. After incubation 204 
at 37 °C for 24 h of 20 μl compound-DNA solution samples 4 μl of color marker was added. The 205 
mixture went through electrophoresis in 0.5% agarose gel in TBE buffer at 1.5 V/cmfor 4 h. After that 206 
DNA was stained with ethidium bromide solution (0.5 μg/ml in TBE) during 20 min. Negative control 207 
was a free plasmid pBR322 DNA solution, and for positive control cisplatin–DNA samples in the same 208 
conditions of all other complexes were prepared. 209 
 210 
2.2.8. Molecular fluorescence 211 
Fluorescence molecular emission measurements were registered with a spectrofluorimeter Kontron 212 
SFM-25 (Bio-Tek Instruments).  213 
Sample preparation: several 3 ml aliquots from a calf thymus DNA 50 μMstandard stocking 214 
solutionwere taken, adding to themnecessary amount (30 μl) of ethidium bromide 5 mM to get 1:1 molar 215 
ratio, and they were incubated for 30 min at 37 °C. Afterwards, growing amounts (0, 20, 40, 60, 80 y 216 
100 μl) of compound stock solution (1.5 mM DMSO/mQ water) were added to different samples, to 217 
obtain different complex concentrations in each one (0, 10, 20, 30, 40 y 50 μM respectively). Emission 218 
spectra were registered between 530 and 670 nm and excitation wavelength was established in 502 nm. 219 
DMSO concentration in final samples was always below 2%. 220 
 221 
2.2.9. Viscosity measurements 222 
DNA solutions viscositymeasurementswere carried outwith a Vibro Viscometer SV-1ª (AND A&N 223 
Company Limited). 224 
Sample preparation: 1ml stock solution 5mMof each compound in DMSO/water (4:1), and 1mMcalf 225 
thymus DNA solutionwere prepared. Afterwards, several aliquots of 1 ml from this last were transferred 226 
to different sterilized tubes, adding then 3 ml of TE buffer, which corresponds with DNA control 227 
solution. For each compound, increasing amounts of stock solution (20, 60 and 100 μl) were added to 228 
reach molar ratios of 0.1, 0.3 and 0.5 DNA: complex, respectively. In all of them viscosity at 25 °C was 229 
measured before and after mixing, and along the time as well (0, 4, 14, 32, 44 and 56 h), keeping 230 
constant temperature with a termostatized water bath for the samples and isobuthyl alcohol bath for 231 
viscometer devices. Again, DMSO concentration in biological samples did not exceed 2%. 232 
 233 
2.2.10. Mass spectrometry 234 
Matrix-assisted laser desorption ionization-time of flight (MALDI-TOF) mass spectra were obtained 235 
with a VOYAGER DE-RP (Applied Biosystems) mass spectrometer provided with a nitrogen laser (337 236 
nm, 3 ns pulsed) and applying 20–25 KV as accelerating voltages. Samples were dissolved in suitable 237 
matrixes (DHB 2,5- dihydroxybenzoic acid, Sigma-Aldrich, 10 mg/ml acetonitrile/H2O 1:1 volume 238 
(0.1% TFA)). 239 
Infusion high resolution electrospray ionization mass spectrometry (ESI-MS) spectra were carried out 240 
with a LC/MSD-TOF (Agilent Technologies) mass spectrometer provided with double nebulizer for 241 
exact mass determination. (See Table S1 in Supplementary information for experimental condition 242 
details). 243 
Liquid chromatography mass spectrometry (LC–MS) experiments were performed on a QSTAR Elite 244 
System Hybrid Quadrupole-TOF LC/MS/MS (AB Sciex) using an Agilent 1100 G13112B pump, and an 245 
Agilent 1200 G1367C automatic sampler provided with a column oven. 246 
Potato carboxypeptidase inhibitor (PCI)-complex and ubiquitincomplex adducts (where complex = 1.7), 247 
were obtained by aqueous solution reaction at neutral pH and temperature of HPLC autosampler (40 248 
°C). Aliquots of 300 μl of PCI and ubiquitin solutions were taken, and it was added with the necessary 249 
amount (μl) of 0.01 M compound stock solution (DMSO/mQ water, 2% maximum DMSO) to obtain 1:1 250 
molar ratio. The system was allowed to react and its evolution was studied by HPLC–MS with 10 μl 251 
sample injection per hour, during 24 h. A Nucleosil 120 C18 10 μm 25 × 0.45 cm column was used for 252 
chromatographic separation using linear gradients of acetonitrile in aqueous solution (A: ammonium 253 
acetate 0.01 M, B: acetonitrile 0–100% flux: 1 ml/min–40 min). A 1:10 split post-column was done for 254 
on-line coupling to the mass spectrometer. Experimental mass spectrometry conditions are described in 255 
the Supplementary information (Table S2). 256 
 257 
2.2.11. Ion mobility mass spectrometry (IMS–MS) 258 
IMS–MS experiments were carried out using a SYNAPT G1 HDMS mass spectrometer (Waters, 259 
Manchester, UK). Samples were placed on a 384-well plate refrigerated at 15 °C and introduced by 260 
automated chip-base nanoelectrospray using a Triversa NanoMate (Advion Bio-Sciences) in positive ion 261 
mode. A reduction of the source pumping speed in the backing region (5.81 mbar) of the mass 262 
spectrometer was done for optimal ion transmission. (For detailed experimental conditions see 263 
Supplementary Table S3) The instrument was calibrated over the m/z range 500–5000 Da using a 264 
solution of cesium iodide. MassLynx vs 4.1 SCN 704 software and Driftscope vs 2.1 software were used 265 
for data processing. Experimental drift times were transformed into collision cross sections (CCS, Ω) by 266 
constructing a calibration curve with proteins of known collision cross-sections. The calibrant lists are 267 
given in Table S4 and the calibration curves are shown in Fig. S2. Experimental drift times for these 268 
calibrants were recorded using identical instrument conditions than the studied complexes. 269 
They were taken 10 μl of 3 mM ubiquitin solution and 20 μl of 1.86 mM PCI solution, and it was added 270 
with the necessary volume of complex E1 and E2 0.01 M stock solutions to obtain 1:1 molar ratio. 271 
Sampleswere incubated for 24 h at 37 °C. Afterwards theywere diluted with 600 μl of ammonium 272 
acetate buffer, and 10 μl of this diluted solution was poured in the sample plate of the Advion Triversa 273 
Nanomate. DMSO concentration never exceeded 2%. 274 
 275 
2.2.12. In vitro cytotoxicity and apoptosis assays on HL-60 cells 276 
 277 
2.2.12.1. Tumor cell lines and culture conditions. The cell line usedwas the human acute promyelocytic 278 
leukemia cell line HL-60 (American Type Culture Collection (ATCC)). Cells were routinely maintained 279 
in RPMI-1640 medium supplemented with 10% (v/v) heat inactivated fetal bovine serum, 2 mmol/l 280 
glutamine, 100 U/ml penicillin, and 100 lg/ml streptomycin (Gibco BRL, Invitrogen Corporation, 281 
Netherlands) in a highly humidified atmosphere of 95% air with 5% CO2 at 37 C. 282 
 283 
2.2.12.2. Cytotoxicity assays. Growth inhibitory effect of the ruthenium complexes on the leukemia HL-284 
60 cell line was measured by the microculture tetrazolium, [3-(4,5-dimethylthiazol-2-yl)-2,5- 285 
diphenyltetrazolium bromide, MTT] assay [26]. Briefly, cells growing in the logarithmic phase were 286 
seeded in 96-well plates (104 cells per  well), and then were treated with varying doses of the ruthenium 287 
complex and the reference drug cisplatin at 37 C for 24 h. For each of the variants tested, four wells 288 
were used. Aliquots of 20 μl of MTT solution were then added to each well. After 3 h, the color formed 289 
was quantified by a spectrophotometric plate reader at 490 nm wavelength. The percentage of cell 290 
viability was calculated by dividing the average absorbance of the cells treated with the complex by that 291 
of the control; IC50 values (drug concentration at which 50% of the cells are viable relative to the 292 
control) were obtained by GraphPad Prism software, version 4.0. 293 
 294 
2.3. Synthesis 295 
 296 
2.3.1. Synthesis of complexes without PPh3 moiety (see Fig. S1) 297 
2.3.1.1. Synthesis of [RuIICl2(p-cymene)]2 (1). A suspension of RuCl3 (0.1 g, 0.36 mmol) in ethanol 298 
(40 ml) was heated under reflux during 8 h with 6 equivalents (2 ml, 18 mmol) of R-α-phellandrene, 299 
keeping the stirring afterwards during 12 h more at room temperature. Solvent was removed under 300 
reduced pressure until an orange precipitate was observed, which was filtered off, washed with cold 301 
methanol and dried under reduced pressure. 302 
Yield: 65%; M.S.[ESI]: m/z 576.9 {M-Cl}+; Anal. Calc. C20H28Cl4Ru2: 39.23% C, 4.61% H; Anal. 303 
Exp.: 39.39% C, 4.51% H; 1H NMR [CDCl3]: δa 5.48, δb 5.35 (dd, J(HH) ≈ 6.0 Hz, 4H, C2,3,5,6-304 
H{ring}), δ 2.93 (sep, J(HH) ≈ 7.0 Hz, H, CH(Me)2), δ 2.16 (s, 3H, CH3{ring}), δ 1.28 (d, JHH ≈ 7.0 305 
Hz, 6H, CH(Me)2); IR: 3052.68 (νCsp2–H), 2961.22 (νCsp3–H), 1468–1386 (νC_C). 306 
 307 
2.3.1.2. Synthesis of [RuIICl2(p-cymene)(4-(2-EtOH)Py)] (2). A suspension of (1) (0.1 g, 0.16 mmol) 308 
and 4-(2-hydroxyethyl)pyridine (300 μl, 2.7 mmol) in methanol (30 ml) was heated under reflux during 309 
7 h, keeping the stirring afterwards during 12 hmore at room temperature. Solvent was removed under 310 
reduced pressure until an orange oil was obtained. With the addition of diethyl ether an orange 311 
precipitate was obtained, which was filtered off, washed with diethyl ether and dried under reduced 312 
pressure. 313 
Yield: 83%; M.S.[ESI]: m/z 394.05 {M+-Cl}; Anal. Calc. C17H22Cl2-NORu: 47.56% C, 5.40% H, 314 
3.26% N; Anal. Exp.: 47.57 %C, 5.35% H, 3.35% N; 1H NMR [CDCl3]: δ 8.88 (d, J(HH) ≈ 6.2 Hz, 2H, 315 
C–H{4-(2-EtOH) Py}), δ 7.18 (d, J(HH) ≈ 6.2 Hz, 2H, C–H{4-(2-EtOH)Py}), δ 5.44–5.21 (2d, J(HH) ≈ 316 
6.0 Hz, 4H, C–H{ring}), δ 3.80 (m, J(HH) ≈ 6.0 Hz, 2H, CH2{4-(2-EtOH)Py}), δ 3.00 (sep, J(HH) ≈ 317 
7.0 Hz, H, CH(Me)2), δ 2.85 (t, J(HH) ≈ 6.0 Hz, 2H, CH2{4-(2-EtOH)Py}), δ 2.11 (s, 3H, CH3{ring}), 318 
δ 1.31 (d, J(HH) ≈ 7.0 Hz, 6H, CH(Me)2); IR: 3463.70 (νOH), 816.35 (νRu–N). 319 
 320 
2.3.2. Synthesis of complexes including PPh3 moiety (see Fig. S1) 321 
2.3.2.1. Synthesis of [RuIICl2(p-cymene)PPh3] (3). A suspension of (1) (0.55 g, 0.9 mmol) and PPh3 322 
(0.6 g, 2.25 mmol) in hexane (30 ml) was heated under reflux during 5 h, keeping the stirring until it 323 
reached room temperature. The red precipitate result was filtered off, washed with hexane and dried 324 
under reduced pressure. 325 
Yield: 82%; M.S.[ESI]: m/z 586.1 {M-Cl}+; Anal. Calc. C28H29Cl2Ru: 59.16% C, 5.14% H; Anal. 326 
Exp.: 58.83% C, 5.04% H; 1H NMR [CDCl3]: δ 7.37–7.83 (m, 15H, PPh3), δa 5.18, δb 4.99 (2d, J(HH) 327 
≈ 6.0 Hz, 4H, C–H{ring}), δ 2.85 (sep, J(HH) ≈ 7.0 Hz, H, CH(Me)2), δ 1.87 (s, 3H, CH3{ring}), δ 1.11 328 
(d, J(HH) ≈ 7.0 Hz, 6H, CH(Me)2); 31P{1H}NMR [CDCl3]: δ 24.16 (s, PPh3); IR: 1091.21 (νP–C), 329 
520.95 (πC–P–C). 330 
 331 
2.3.2.2. Synthesis of [RuIICl(p-cymene)(3-picoline)PPh3][PF6] (4). 332 
A suspension of (3) (0.1 g, 0.18 mmol), KPF6 (0.04 g, 0.2 mmol) and 3-methylpyridine (3-picoline, 400 333 
μl, 4.0 mmol) in methanol (30 ml) was stirred during 24 h at room temperature. Solvent was removed 334 
under reduced pressure until a yellow oil was obtained.With the addition of diethyl ether a yellow 335 
precipitate was obtained, which was filtered off, washed with diethyl ether and dried under reduced 336 
pressure. 337 
Yield: 78%;M.S.[ESI]: m/z 626.13 {M+}; Anal. Calc. C34H36ClF6NP2Ru: 52.96% C, 4.71% H, 1.82% 338 
N; Anal. Exp.: 53.13% C, 4.83, 1.82% N; 1HNMR [CDCl3]: δ 8.76 (d, J(HH)≈5.0 Hz, H, C–H{3-339 
picoline}), δ 8.53 (s, H,C–H {3-picoline}), δ 7.27–7.57 (m, 16H, PPh3, 3-picoline), δ 7.04 (d, J(HH) ≈ 340 
2.0 Hz, H, C–H{3-picoline}), δ 5.95–5.30 (4d, J(HH) ≈ 5.0 Hz, 4H, C–H{ring}), δ 2.18 (sep, J(HH) ≈ 341 
6.4 Hz, H, CH(Me)2), δ 2.12 (s, 3H, CH3{3-picoline}), δ 1.65 (s, 3H, CH3 {ring}), δ 1.10 (2d, J(HH) ≈ 342 
7.0 Hz, 6H, CH(Me)2); 31P{1H}NMR [CDCl3]: δ 37.3 (s, PPh3), δ −144.1 (sep, J(PF) ≈ 713 Hz, PF6 343 
−), 19F{1H}NMR [CDCl3]: δ −73 (d, J(FP) ≈ 713 Hz, PF6 −); IR: 1093.02 (νP–C), 840.39 (νRu–N), 344 
700.75 (νP–F). 345 
 346 
2.3.2.3. Synthesis of [RuIICl(p-cymene)(3,4-lutidine)PPh3][PF6] (5). A suspension of (3) (0.1 g, 0.18 347 
mmol), KPF6 (0.04 g, 0.2 mmol) and 3,4- dimethylpyridine (3,4-lutidine, 200 μl, 1.8 mmol) in methanol 348 
(30 ml) was heated under reflux during 7 h, keeping the stirring afterwards during 12 h more at room 349 
temperature. Solvent was removed under reduced pressure until an orange oil was obtained. With the 350 
addition of diethyl ether an orange precipitate was obtained, which was filtered off, washed with diethyl 351 
ether and dried under reduced pressure.  352 
Yield: 84%;M.S.[ESI]:m/z 640.15 {M+}; Anal. Calc. C35H38ClF6NP2Ru-H2O: 52.34 %C, 5.02% H, 353 
1.74% N; Anal. Exp.: 52.39% C, 4.60% H, 1.84% N; 1H NMR [CDCl3]: δ 8.60 (d, J(HH)≈5.3 Hz, H, 354 
C–H{3,5-lutidine}), δ 8.35 (s, H, C–H{3,5-lutidine}), δ 7.26–7.5 (m, 15H, PPh3), δ 6.90 (d, J(HH) ≈ 5.3 355 
Hz, H, C–H{3,5-lutidine}), δ 5.98–5.28 (4d, J(HH) ≈ 5.7 Hz, 4H, C–H{ring}), δ 2.21 (sep, J(HH) ≈ 7.0 356 
Hz, H, CH(Me)2), δ 2.15 (s, 3H, CH3{3,5-lutidine}), δ 1.99 (s, 3H, CH3{3,5-lutidine}), δ 1.64 (s, 3H, 357 
CH3 {ring}), δ 1.11 (2d, J(HH) ≈ 5.0 Hz, 6H, CH(Me)2); 31P{1H}NMR [CDCl3]: δ 37.7 (s, PPh3), δ 358 
−144.1 (sep, J(PF) ≈ 713 Hz, PF6 −), 19F{1H} NMR [CDCl3]: δ −73 (d, J(FP) ≈ 713 Hz, PF6 −); IR: 359 
1092.35 (νP–C), 840.39 (νRu–N), 700.30 (νP–F). 360 
 361 
2.3.2.4. Synthesis of [RuIICl(p-cymene)(3,5-lutidine)PPh3][PF6] (6). A suspension of (3) (0.1 g, 0.18 362 
mmol), KPF6 (0.04 g, 0.2 mmol) and 3,5- dimethylpyridine (3,5-lutidine, 200 μl, 1.8 mmol) in methanol 363 
(30 ml) was heated under reflux during 7 h, keeping the stirring afterwards during 12 h more at room 364 
temperature. Solvent was removed under reduced pressure until an orange oil was obtained. With the 365 
addition of diethyl ether an orange precipitate was obtained, which was filtered off, washed with diethyl 366 
ether and dried under reduced pressure. 367 
Yield: 89%; M.S.[ESI]: m/z 640.15 {M+}; Anal. Calc. C35H38ClF6NP2- Ru-H2O: 52.34% C, 5.02% 368 
H, 1.74% N; Anal. Exp.: 52.61% C, 4.72% H, 1.89% N; 1H NMR [CDCl3]: δ 8.43 (s, 2H, C-H{3,5-369 
lutidine}), δ 7.27–7.50 (m, 15H, PPh3), δ 7.11 (s, H, C–H{3,5-lutidine}), δ 5.99–5.35 (4d, J(HH) ≈ 5.4 370 
Hz, 4H, C–H{ring}), δ 2.20 (sep, J(HH) ≈ 7.0 Hz, H, CH(Me)2), δ 2.11 (s, 6H, 2CH3{3,5-lutidine}), δ 371 
1.64 (s, 3H, CH3{ring}), δ 1.11 (2d, J(HH) ≈ 7.5 Hz, 6H, CH(Me)2); 31P{1H}NMR [CDCl3]: δ 38.1 (s, 372 
PPh3), δ −144.1 (sep, J(PF) ≈ 713 Hz, PF6 −), 19F{1H}NMR [CDCl3]: δ −73 (d, J(FP) ≈ 713 Hz, PF6 373 
−); IR: 1092.65 (νP–C), 836.70 (νRu–N), 700.41 (νP–F). 374 
 375 
2.3.2.5. Synthesis of [RuIICl(p-cymene)(4-(2-EtOH))PPh3][PF6] (7). A suspension of (3) (0.1 g, 0.18 376 
mmol), NH4PF6 (0.03 g, 0.2 mmol) and 4-(2-hydroxyethyl)pyridine (300 μl, 2.7 mmol) in methanol (30 377 
ml) was heated under reflux during 7 h, keeping the stirring afterwards during 12 h more at room 378 
temperature. Solvent was removed under reduced pressure until a yellow oil was obtained. After the 379 
addition of some drops of DMSO, a brown precipitate was obtained with the addition of H2O. The 380 
precipitate obtained was filtered off, washed with deionized water and dried under reduced pressure. 381 
Yield: 69%; M.S.[ESI]: m/z 656.14 {M+}; Anal. Calc. C35H38ClF6NOP2- Ru-NH4: 48.67% C, 4.74% 382 
H, 3.66% N; Anal. Exp.: 49.16% C, 4.66%, 3.57% N; 1H NMR [CDCl3]: δ 8.73 (d, J(HH) ≈ 6.3 Hz, 383 
2H, C–H{4-(2-EtOH)Py}), δ 7.27–7.50 (m, 15H, PPh3), δ 7.02 (d, J(HH) ≈ 6.3 Hz, 2H, C–H{4-(2- 384 
EtOH)Py}), δ 5.93–5.25 (4d, J(HH) ≈ 6.0 Hz, 4H, C–H{ring}), δ 3.77 (m, J(HH) ≈ 7.0 Hz, 2H, CH2{4-385 
(2-EtOH)Py}), δ 2.76 (t, J(HH) ≈ 6.0 Hz, 2H, CH2{4-(2-EtOH)Py}), δ 2.24 (sep, J(HH) ≈ 7.0 Hz, H, 386 
CH(Me)2), δ 1.66 (s, 3H, CH3{ring}), δ 1.10 (d, J(HH) ≈ 7.0 Hz, 6H, CH(Me)2); 31P{1H}NMR 387 
[CDCl3]: δ 37.1 (s, PPh3), δ −144.1 (sep, J(PF) ≈ 713 Hz, PF6 −), 19F{1H}NMR [CDCl3]: δ −73 (d, 388 
J(FP) ≈ 713 Hz, PF6 −); IR: 3533.84 (νOH), 1093.69 (νP–C), 840.42 (νRu–N), 700.86 (νP–F). 389 
 390 
2.3.2.6. Synthesis of [RuIICl(p-cymene)(PPh3)2][PF6] (8). A suspension of (3) (0.1 g, 0.18 mmol), 391 
KPF6 (0.04 g, 0.2 mmol) and PPh3 (0.1 g, 0.4 mmol) in methanol (30 ml) was stirred during 2 h at 35 392 
°C. Solvent was removed at room temperature under reduced pressure until a yellow oil was obtained. 393 
With the addition of hexane a yellow precipitate was obtained, which was filtered off, washed with 394 
ethanol/hexane 1:2 and dried under reduced pressure. 395 
Yield: 78%; M.S.[ESI]: m/z 795.16 {M+}; Anal. Calc. C46H44ClF6P3Ru: 58.76% C, 4.72% H; Anal. 396 
Exp.: 58.56% C, 4.79% H; 1H NMR [CDCl3]: δ 7.45–7.22 (m, 30H, 2PPh3), δ 5.60–5.00 (2d, J(HH) ≈ 397 
6.4 Hz, 4H, C–H {ring}), δ 2.70 (sep, J(HH) ≈ 7.0 Hz, H, CH(Me)2), δ 1.22 (d, J(HH) ≈ 7.0 Hz, 6H, 398 
CH(Me)2), δ 1.10 (s, 3H, CH3{ring}); 31P{1H}NMR [CDCl3]: δ 20.67 (s, PPh3), δ −144.1 (sep, J(PF) 399 
≈ 713 Hz, PF6 −), 19F {1H}NMR [CDCl3]: δ −73 (d, J(FP) ≈ 713 Hz, PF6 −); IR: 1089.04 (νP–C), 400 
831.44 (νRu–N), 699.03 (νP–F), 516.46 (πC–P–C). 401 
 402 
2.4. Crystallographic analysis 403 
 404 
Single crystal X-ray diffraction experiments were carried out with suitable selected crystals of 405 
(2),(4),(5),(6) and (7), mounted at the tip of a glass fiber on an ENRAF-NONIUS CAD4 producing 406 
graphite monochromatic Mo Kα radiation (λ = 0.71073 Å). The structures were solved using the 407 
WINGX package. A summary of the crystal data can be seen in Table 1. Core length and refinements 408 
parameters are included in the Supplementary information (Tables S5). Images of each one of the 409 
complexes analyzed can be seen in Figs. 2–6. CCDC 857319–857323 contain the Supplementary 410 
crystallographic data for this paper. These data can be obtained free of charge fromthe Cambridge 411 
Crystallographic Data Centre via www.ccdc.cam.ac.uk/data_request/cif. 412 
  413 
3. RESULTS AND DISCUSSION 414 
 415 
3.1. DNA interaction studies 416 
 417 
3.1.1. Circular dichroism 418 
The circular dichroism spectrum of calf-thymus DNA in TE buffer shows a negative band with λmax = 419 
46 nm and a positive band with λmax = 275 nm, characteristics of right-handed B-form DNA [27]. 420 
Although most of theminduced changes in CD spectrumnot very significant (with notable negative and 421 
positive bands intensity decrease), complex (2) and complex (8) caused important changes in ellipticity 422 
of calf thymus DNA and so distortion of its secondary structure (Fig. 7). 423 
 424 
3.1.2. Agarose gel electrophoresis 425 
Calf thymus DNA contains two main conformational topoisomers, open circular (OC) and covalently 426 
closed circular (CCC). Agarose gel electrophoresis studies can show the distortion of tertiary structure 427 
due to the interaction between drugs and DNA. The image in Fig. 8 shows calf thymus DNA migration 428 
through agarose gel for untreated DNA and several DNA-metallic complex adducts. 429 
As seen below any of these complexes distorts DNA tertiary structure in a way able to change the 430 
topoisomer's distribution pattern. Only DNA–cisplatin adducts show the typical coalescence of both CC 431 
and CCC signals due to the formation of cis covalent bonding adducts. 432 
These results suggest that the interaction between DNA and current ruthenium complexes could be 433 
different from the one established between DNA and cisplatin. It is well known that DNA–cisplatin 434 
adducts are preferently intrastand cis covalent binding, so it can be concluded that current ruthenium 435 
complexes must bind DNA in a different way, since its effect in DNA agarose gel electrophoresis 436 
migration is completely different. 437 
 438 
3.1.3. Molecular fluorescence 439 
Based on previous results, ethidium bromide quenching studies were carried out to elucidate whether π-440 
stacking bonding could have any contribution to DNA ruthenium complex interaction or not. Ethidium 441 
bromide is a typical intercalator that can bond DNA nitrogen bases intercalating between them. 442 
Ethidium bromide displacement studies are one of the most simple and potent tools to find out if any 443 
compound can bind DNA nitrogen bases through π-stacking interaction [28]. 444 
Images on Fig. 9 show the molecular fluorescence spectra of DNA–cisplatin (negative control), DNA-9-445 
acridine (positive control) and DNA-ruthenium complex 2 and 8 adducts. As seen below, for positive 446 
control decrease intensity of molecular fluorescence occurs when increasing drug ratio due to the 447 
consequent higher ethidium bromide displacement, and so increasing fluorescence quenching. On the 448 
other hand, negative control, shows no molecular fluorescence signal variation, as expected for 449 
compounds that are not able to stand π-stacking interactions with DNA nitrogen bases. See additional 450 
spectra for all compounds in the Supplementary information (Fig. S4). 451 
These plots showed intensity decrease pattern for all the ruthenium complexes except for complex 2, the 452 
only one lacking PPh3moiety in its structure. Different amounts of decrease was found for each one of 453 
them, achieving highest quenching values for complex 8, since it includes two PPh3 groups in its 454 
structure. These results suggest that PPh3 presence could induce intercalation between nitrogen bases 455 
through π-stacking based interactions. 456 
 457 
3.1.4. Viscosity measurements 458 
Optical photophysical probes provide necessary, but not sufficient clues to support a binding model. 459 
Hydrodynamic measurements (i.e., viscosity and sedimentation) that are sensitive to length change are 460 
regarded as the least ambiguous and themost critical tests of a bindingmodel in solution in absence of 461 
crystallographic structural data [29]. A classical intercalation model results in lengthening the DNA 462 
helix as base pairs are separated to accommodate the bound ligand, leading to the increase of DNA 463 
viscosity. In contrast, non-intercalative model, could bend or kink the DNA helix, reduce its effective 464 
length, and concomitantly, its viscosity. In addition, electrostatic or minor groove binding (capable of 465 
EtBr quenching in some occasions) has no influence on DNA viscosity [30]. Fig. 10 shows the change 466 
in viscosity of several calf thymus DNA solutions in TE when treated with increasing ratios of 467 
ruthenium complexes. 468 
As seen in Fig. 10 all complexes cause an important increase in DNA solutions viscosity when 469 
increasing its concentration, except the only one lacking PPh3 moiety in its structure. This phenomenon 470 
confirms the intercalative model induced by PPh3 plane rings, probably in combination with pyridine 471 
derivate ring as a π-stacking sandwich system. In addition, higher increase in viscosity takes place for 472 
complex 8, again, the one with more PPh3 moieties included in its structure. 473 
 474 
3.1.5. Atomic force microscopy 475 
Ruthenium complex interaction with pBR322 DNA in HEPES buffer solution was studied by atomic 476 
force microscopy (AFM). The results obtained are depicted in Fig. 11. As can be seen, ruthenium 477 
complex binding causes DNA chain aggregation (complex 2), DNA chain opening (complex 6), kinks 478 
(complexes 6, 7), cross-linking and supercoiling (complexes 4–7, remarkably complex 5), and even 479 
chain fracture (complexes 5, 6), showing very different DNA morphologies related to untreated DNA. 480 
Once more, pBR322-complex 2 system shows different topoisomer morphologies compared to the rest 481 
of ruthenium complexes, which is consistent with the intercalation binding model proposed for all of 482 
them except for complex 2. 483 
 484 
3.2. Protein interaction studies 485 
 486 
Although DNA is considered as the primary target for most of the metallo-drugs studied so far [31], this 487 
belief is based mainly on studies carried out for platinum based anticancer compounds [32]. However, 488 
mechanism of action of ruthenium-based anticancer compounds is comparatively unexplored, although 489 
it is clear that ruthenium compounds interact more weakly with DNA relative to platinum complexes 490 
[33]. There is evidence suggesting that ruthenium compounds might directly interfere with specific 491 
proteins involved in signal transduction pathways and/or alter cell adhesion and transduction processes 492 
[34–36]. With this frame, ruthenium complex reactivity studies in the presence of model and specific 493 
proteins (ubiquitin and potato carboxypeptidase inhibitor-PCI respectively) have been carried out. 494 
Ubiquitin is amodel protein that playsmany different rolls inmetabolism, and it is ubiquitous in the 495 
organism. On the other hand, PCI is a specific protein that can act as an antagonist of human epidermal 496 
grow factors (EGF) which are over expressed in tumor cells [37,38]. In fact, PCI is considered as a 497 
cytostatic agent, able to block the cell cycle between G0 and G1 phases selectively in cancer cells, 498 
without directly inducing apoptosis [39]. All these phenomena suggest the capability of PCI to 499 
vehiculize ruthenium metallo-drugs in a selective way to tumor cells (see structures of both proteins in 500 
Fig. S5 in the Supplementary information). 501 
 502 
3.2.1. HPLC–MS ruthenium complex–protein interaction study 503 
High-resolution ESI MS has been known as a potent tool to study covalent and non-covalent ligand–504 
biomolecule interactions [40–42] and to screen complex mixtures of metabolites, often without the need 505 
for chromatographic separation of the adducts prior to analysis [43–45]. In this case, HPLC–MS studies 506 
allowed to evaluate the interaction of ruthenium complexes with both model and specific proteins, as 507 
well as to elucidate the implications of the presence of PPh3 moiety in this interaction. 508 
Graphics on Figs. 12 and 13 show a summary of the decrease of free protein signal while increasing 509 
ruthenium complex–protein adduct solution content within the time (see all complete mass spectra in the 510 
Supporting information, Fig. S6). 511 
In the case of PCI protein (Fig. 12), when PPh3 ligand is present the kinetics of the reactions is very 512 
influenced, taking more time to detect the PCI-ruthenium complex adduct and in smaller quantities. On 513 
the other hand, when no PPh3 moiety is present, almost all the free protein content disappears in very 514 
short period of time, to be mainly in PCIruthenium complex adduct form. 515 
Added to that, for ubiquitin protein (Fig. 13), it was not possible to detect the presence of ubi-ruthenium 516 
complex adduct when PPh3 ligand was present. All that data suggest that the PPh3 presence affects in a 517 
very important manner to the adduct formation process kinetics, which could have very important 518 
consequences in the detoxification processes and/or in the delivery of these drugs and cell uptake, 519 
allowing slower pharmacokinetics (which usually means less secondary effects) and higher resistance to 520 
drug removal in natural detoxification processes. 521 
 522 
3.2.2. IMMS — Ion mobility mass spectrometry studies 523 
Ion mobility mass spectrometry can provide information on the physical size and shape of ionized 524 
molecules [46] and previous works on related Ru-based complexes have demonstrated the use of this 525 
technique for the separation of geometrical isomers and the calculation of their collision cross-sections 526 
(CCSs) [47]. 527 
In this technique, basically, a liquid sample is ionized and injected into a drift chamber containing 528 
neutral gas at a controlled pressure (e.g., 0.5 mbar of nitrogen gas). Under the influence of an electric 529 
field, gaseous ions undergo IM separation according to the resistance they experience through their 530 
collision with neutrals, which depends on their collision cross section-to-charge ratio (Ω/z). After 531 
separation, ions are sampled by a mass spectrometer and analyzed according to their mass-to-charge 532 
(m/z) ratio. Therefore, integrated IMS–MS has the capability of separating ions not only by their mass 533 
but also by their size, shape and charge state. IM–MS offers an extra degree of analytical opportunity 534 
whereby conformational ensembles of species of equivalent mass, or the same m/z, can be separated on 535 
account of their physical shape and then mass analyzed in a single, rapid experiment. The experimental 536 
drift times (arrival times) can be correlated to collision cross sections by performing calibration curves 537 
with protein standards of known cross sections analyzed under identical instrumental conditions. 538 
Significant changes in CCS should be evaluated as they reflect conformational changes that could affect 539 
some functions of the protein.More detailed information about IMS–MS can be found in the literature 540 
[48]. 541 
As mentioned before, PCI protein can act as a vehicle for anticancer drugs towards specific cancer cells 542 
in case the binding of the metal complexes doesn't distort the protein structure, since it is an antagonist 543 
of EGFs.With the aimof studying the conformational changes of PCI and ubiquitin due to the ruthenium 544 
complexes binding IMS–MS experiments were carried out. 545 
MS spectra shown in Fig. 14 demonstrate the binding of different fragments of ruthenium complexes to 546 
both PCI and ubiquitin, and reinforce previous conclusions out of HPLC–MS studies. As can be seen, 547 
again, the presence of PPh3 moiety affords slower kinetics and smaller yields of protein–metal complex 548 
binding, which should have important consequences in terms of drug distribution and detoxification 549 
mechanisms. 550 
Table 2 shows the CCSs obtainedwhen relating the drift times out of the IMS–MS experiments for each 551 
molecule reaching the detector, with the cross section calibration curve made with protein standards (see 552 
also Fig. S2 in the Supplementary information). 553 
As shown in the table, the differences in CCS upon ligand interaction with UBI and PCI lay between 554 
0.02 and 11.7% which suggests no significant conformational changes in the three-dimensional gas-555 
phase protein structure. That would support both the possibility of drug delivery by model proteins as 556 
ubiquitin and the possibility of specific vehiculization towards cancer cells by specific proteins as PCI. 557 
 558 
3.3. Cytotoxicity studies 559 
 560 
Cytotoxicity studies were carried out for complexes 2–7 in HL60 Human Leukemia Tumor Cell Line, 561 
affording IC50 values shown in Table 3. 562 
The cytotoxic properties of the complexes including PPh3 ligand in its structure correspond to values 563 
comparable to the cytotoxicity obtained for cis-platin and ruthenium complexes active against cancer 564 
cell lines in similar experiments [49] (notice that rutheniumcomplexes undergo some special processes, 565 
such as hydrolysis and different bindings compared to cis-platin), while the only one that lack this 566 
moiety raises over 200 μM, so it cannot be considered an active drug towards this type of tumor cell 567 
line. 568 
These results added to the fact that previous investigations carried out in our group [50] in which most 569 
of the complexes studied in the present work, but lacking PPh3 moiety, were evaluated as antitumor 570 
drugs showing poor antiproliferative properties, strongly suggest an important increment of the 571 
antitumor properties of ruthenium complexes due to PPh3 presence. 572 
  573 
4. CONCLUSIONS 574 
 575 
Several new organometallic ruthenium complexes, some of them including PPh3 ligands, have been 576 
synthesized and characterized. DNA interaction studies have demonstrated the capability of these 577 
complexes to bind DNA and distort its secondary and tertiary structure notably. Ethidium bromide 578 
displacement experiments and viscosity measurements prove that those complexes including PPh3 579 
moiety in its structure are able to intercalate into DNA base pairs, whereas those without PPh3 ligand 580 
bind DNA only in a covalentmanner. Protein interaction studies have shown the capability of these 581 
complexes to bind as well as to model and specific proteins, demonstrating slower kinetics and smaller 582 
binding yields when PPh3 group is present, presumably due to steric impediments. These effects could 583 
have important consequences in drug cell up-taken and/or detoxification mechanisms. Finally, 584 
cytotoxicity studies show that IC50 values in the range of the ones obtained for cis-platin, considered a 585 
positive control for antiproliferative tumor cell studies, in all cases except for the complex lacking PPh3 586 
ligand. That result proves definitively the increment of ruthenium complex antiproliferative potential 587 
due to the PPh3 presence, presumably owing to its capability to intercalate between DNA base pairs. 588 
Therefore IMMS studies demonstrate no change in conformational structure of the proteins due to 589 
ruthenium complex binding which supports a possible role of PCI as a vehiculizing agent to specific 590 
tumor cells for ruthenium complexes. 591 
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.677 
Legends to figures 678 
 679 
Figure 1 Organometallic ruthenium(II) complex structure. 680 
 681 
Figure 2. ORTEP representation of crystallographic structure of complex 2. 682 
 683 
Figure 3 ORTEP representation of crystallographic structure of complex 4. 684 
 685 
Fig. 4 ORTEP representation of crystallographic structure of complex 5. 686 
 687 
Figure 5. ORTEP representation of crystallographic structure of complex 6.  688 
 689 
Figure 6. ORTEP representation of crystallographic structure of complex 7. 690 
 691 
Figure 7. CD spectra of DNA–cisplatin and DNA–complex 8 adducts. 692 
 693 
Fig. 8. Agarose gel electrophoresis image of untreated DNA (1), DNA-rutheniumcomplex 2, 4–8 (2, 3–694 
7), and DNA–cisplatin (8) adducts. 695 
 696 
Fig. 9. Fluorescence emission spectra of DNA-EtBr system treated with some compounds showing 697 
different performances depending on the presence of PPh3 moiety. 698 
 699 
Fig. 10. Viscosity evolution for calf thymus DNA solutions treated with synthesized ruthenium 700 
complexes. 701 
 702 
Fig. 11. Atomic force microscopy (AFM) images of pBR322-DNA plasmid solutions treated with 703 
synthesized ruthenium complexes. 704 
 705 
Fig. 12. HPLC–MS tuned spectra of PCI-complex 2, 7 solution. Go to Supplementary information Fig. 706 
S6 to see all complete mass spectra. 707 
 708 
Fig. 13. HPLC–MS tuned spectra of Ubi-complex 2 solution. Go to Supplementary information Fig. S6 709 
to see all complete mass spectra. 710 
 711 
Fig. 14. MS spectra of PCI, UBI, complex 2 and complex 7 combination solutions. 712 
  713 











  725 











  737 






  744 






  751 
 752 




  757 




  762 




  767 










  778 






  785 





  791 






  798 




  803 




  808 






  815 






  822 
Table 2. Cross-section variations of different detected adducts. (a) No DMSO in solution. (b) 2% 823 
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Table 3. IC50 values at 24 h for HL60 leukemia tumor cell line. 833 
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